- Coriolis Pharma has appointed Dr. Teun van der Heide as chief executive officer, effective November 2, 2026.
- Van der Heide previously held senior leadership roles at Lonza and served as chief business officer at ten23 health. His priorities include strengthening customer relationships and expanding the company’s global presence, particularly in the United States.
Coriolis Pharma has appointed Dr. Teun van der Heide as chief executive officer, effective November 2, 2026. The appointment brings a new executive leader to the biopharmaceutical research and development partner as it focuses on customer relationships, service quality, and international expansion.
Van der Heide brings leadership and commercial experience from the pharmaceutical and life sciences industries. At Lonza, he headed the Bioscience Solutions and Capsule Delivery Solutions (Capsugel) business units. Most recently, he served as chief business officer at ten23 health, overseeing its business development and commercial activities.
In his new role, van der Heide will focus on strengthening customer relationships, maintaining service quality, identifying growth opportunities, and expanding Coriolis Pharma’s global presence, particularly in the United States. The company said his industry experience and understanding of the CDMO sector will support these priorities.
“We are delighted to welcome Teun to Coriolis Pharma. His industry experience, entrepreneurial mindset, and proven commercial leadership, particularly as Chief Business Officer at ten23 health, make him exceptionally well positioned to strengthen our business and drive our next phase of growth in Europe, the United States, and beyond.”
Dr. Michael Wiggenhorn, co-founder and board member of the company
Wiggenhorn also thanked Silvia Steyrer-Gruber for her leadership and contributions over the past four and a half years.
